Clinical Trials Browser

Phase 3 × Pathologic Complete Response × ruxolitinib × Clear all

NCT04934670 2024-08-27

2002

Phase 3 Terminated

12 enrolled 12 charts

Pathologic Complete Response, Lymphoma, Follicular